Oryzon Genomics (XMAD:ORY) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:ORY Oryzon Genomics SA XMAD:ORY
31 GF Score
Price €2.79
View Full Analysis

What is Oryzon Genomics Net Loan?

Net Loan only applies to banks and insurance companies.

XMAD:ORY
31GF Score
Oryzon Genomics SA XMAD:ORY
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Business Description

Other Exchanges ORYZF:USA0RDB:UKORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a Spanish clinical-stage biopharmaceutical company focused on epigenetics-based therapeutics. It develops small-molecule inhibitors of epigenetic enzymes, principally lysine-specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6), for oncology and central nervous system disorders. Its lead candidates include iadademstat (ORY-1001), an LSD1 inhibitor in clinical trials for acute myeloid leukemia and small cell lung cancer, and vafidemstat (ORY-2001), an LSD1 inhibitor being studied in neuropsychiatric and neurodegenerative conditions such as borderline personality disorder, Alzheimer's disease, and multiple sclerosis. The company also pursues earlier-stage programs and biomarker-driven precision medicine approaches. Oryzon is headquartered in Barcelona, Spain, and is listed on the Spanish continuous market. It generates no significant product revenue, funding operations through equity financings, licensing arrangements, and research collaborations with academic and pharmaceutical partners.
31GF Score

Get the complete analysis for XMAD:ORY

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.79
Price